Short answer · Medically reviewed summary · Last updated: 2023-07-13
Pyruvate Carboxylase Deficiency (PCD) is a rare genetic disorder that affects the body's ability to convert pyruvate into energy. It is an autosomal recessive disorder, meaning that both parents must carry the defective gene for a child to be affected.
What is the prevalence of Pyruvate Carboxylase Deficiency?
Prevalence of Pyruvate Carboxylase Deficiency: how many people are affected worldwide, differences by sex and region, with sources.
Pyruvate Carboxylase Deficiency (PCD) is a rare genetic disorder that affects the body's ability to convert pyruvate into energy. It is an autosomal recessive disorder, meaning that both parents must carry the defective gene for a child to be affected. PCD is caused by mutations in the PC gene, which encodes the enzyme pyruvate carboxylase.
The prevalence of PCD is estimated to be very low, with only a few hundred cases reported worldwide. Due to its rarity, it is challenging to determine the exact prevalence of this disorder. PCD has been reported in various ethnic groups, suggesting that it is not specific to any particular population.
PCD can present with a wide range of symptoms, including developmental delay, intellectual disability, seizures, hypotonia, and metabolic acidosis. The severity of symptoms can vary among affected individuals, making diagnosis and management complex.
Early diagnosis and intervention are crucial for individuals with PCD to optimize their outcomes. Genetic testing and metabolic evaluations are typically used to confirm the diagnosis. Treatment options may include dietary modifications, such as a high-carbohydrate and low-protein diet, as well as specific medications to manage symptoms.
Research efforts are ongoing to better understand the underlying mechanisms of PCD and develop targeted therapies. Genetic counseling is recommended for families with a history of PCD or those at risk of being carriers.
